You Position: Home > Paper
Nicardipine reverses the resistance of human Pancreatic carcinoma Patu8988 cell line to Pemetrexed
( views:218, downloads:8 )
- Author:
- No author available
- Journal Title:
- WORLD CHINESE JOURNAL OF DIGESTOLOGY
- Issue:
- 2
- DOI:
- 10.3969/j.issn.1009-3079.2010.02.005
- Key Word:
- 胰腺癌;培美曲塞;耐药;尼卡地平
Abstract： 目的:探讨ABCG2拮抗剂-尼卡地平在体外安全剂量下能否逆转耐药,为临床应用提供实验基础.方法:采用噻唑蓝法(MTT)测定尼卡地平对Patu8988亲本和耐药细胞的安全使用浓度,测定单用培美曲塞和联合安全剂量的尼卡地平分别对两株细胞的IC50变化;分别采用DAPI核染色和细胞流式分析在耐药细胞中单用培美曲塞组和联合尼卡地平组凋亡差异.结果:MTT结果显示尼卡地平在浓度<4.85μmol/L(2.5 mg/L)时对细胞基本无不良反应,单用培美曲塞和联合安全剂量的尼卡地平对Patu8988亲本株细胞IC50无明显差异,而对耐药株细胞IC50有差异(P<0.05).流式细胞分析在耐药细胞中联合尼卡地平组凋亡比例高于单用培美曲塞组(32.27%±2.8% vs 50.5%±4.2%,P<0.05).结论:安全剂量下尼卡地平能提高胰腺癌Patu8988耐药细胞株对培美曲塞的敏感性.而对其亲本株无作用.
- [1]严伟,石欣,葛梓,等.胰腺癌细胞株Puta8988对培美曲塞产生获得性耐药的分子生物学机制初步研究[J].2009,(2).
- [2]Bates SE,Robey RW,Polgar O.ABCG2: structure, function and role in drug response.[J].2008,4(1).
- [3]姚进,黄强,刁艺,等.胶质瘤SP细胞耐药靶分子ABCG2的实验研究[J].2008,(1).
- [4]Zhou XF,Coburn RA,Yang X,etc.Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.[J].2005,33(8).
- [5]Sharom FJ.ABC multidrug transporters: structure, function and role in chemoresistance.[J].2008,9(1).
- [6]Nakagawa H,Ishikawa T.Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics.[J].2009,8(1).
- [7]Hegedus C,Szakacs G,Homolya L,etc.Ins and outs of the ABCG2 multidrug transporter: an update on in vitro functional assays.[J].2009,61(1).
- [8]Lordick F,Zeuzem S,Heinemann V,etc.Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial.[J].2007,18(4).
- [9]Tom, Budiharto,Karin, Haustermans,Eric, Van Cutsem,etc.A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.[J].2008,3.